middle.news
Starpharma’s FY25 Revenue Soars 183% as Loss Narrows to $10M
11:36pm on Friday 29th of August, 2025 AEST
•
Biotechnology
Read Story
Starpharma’s FY25 Revenue Soars 183% as Loss Narrows to $10M
11:36pm on Friday 29th of August, 2025 AEST
Key Points
FY25 revenue rises 183% to $4.9 million driven by research and product sales
Reported loss narrows 31% to $10 million with reduced R&D expenditure
Cash balance strong at $15.4 million plus anticipated $3.7 million R&D tax refund
Growth fueled by Petalion Therapeutics collaboration and VivaGel® BV, Viraleze sales
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
STARPHARMA HOLDINGS (ASX:SPL)
OPEN ARTICLE